[HTML][HTML] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner, ME Cooper, D De Zeeuw… - New England journal …, 2001 - Mass Medical Soc
Background Diabetic nephropathy is the leading cause of end-stage renal disease.
Interruption of the renin–angiotensin system slows the progression of renal disease in …
Interruption of the renin–angiotensin system slows the progression of renal disease in …
Losartan: lessons learned from the RENAAL study
S Shahinfar, PA Lyle, Z Zhang, WF Keane… - Expert Opinion on …, 2006 - Taylor & Francis
Renal and cardiovascular diseases associated with Type 2 diabetes are increasing at rapid
rates, and are significant burdens to patients and healthcare systems. The RENAAL …
rates, and are significant burdens to patients and healthcare systems. The RENAAL …
[HTML][HTML] Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study
S Shahinfar, TZ Dickson, T Ahmed, Z Zhang, D Ramjit… - Kidney international, 2002 - Elsevier
Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL
Study. Background Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II …
Study. Background Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II …
Losartan and end‐organ protection—lessons from the renaal study
PR Kowey, TZ Dickson, Z Zhang… - … Indexed and Peer …, 2005 - Wiley Online Library
Abstract Background: The Reduction in ENdpoints with the Angiotensin Antagonist Losartan
(RENAAL) study reported that losartan delayed the progression of renal disease in patients …
(RENAAL) study reported that losartan delayed the progression of renal disease in patients …
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL
B Egan, G Gleim, J Panish - Current medical research and opinion, 2004 - Taylor & Francis
Objective: To review outcomes of diabetic patients treated with losartan in two recent
randomized, double-blind, clinical trials and compare outcomes to similar studies in …
randomized, double-blind, clinical trials and compare outcomes to similar studies in …
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study
OBJECTIVE—Asia is predicted to have the largest population of patients with diabetes who
are at high risk for renal disease. In the Reduction of Endpoints in NIDDM with the …
are at high risk for renal disease. In the Reduction of Endpoints in NIDDM with the …
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
Abstract Background The Reduction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan (RENAAL) study has previously shown losartan to confer significant …
Antagonist Losartan (RENAAL) study has previously shown losartan to confer significant …
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study
WF Keane, PA Lyle - American Journal of Kidney Diseases, 2003 - Elsevier
Background: Diabetic nephropathy has become the single most important cause of end-
stage renal disease (ESRD) worldwide. Strategies to slow the rate of loss of renal function in …
stage renal disease (ESRD) worldwide. Strategies to slow the rate of loss of renal function in …
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation
WH Herman, S Shahinfar, GW Carides… - Diabetes …, 2003 - Am Diabetes Assoc
OBJECTIVE—To evaluate the within-trial effect of losartan and conventional
antihypertensive therapy (CT) compared with placebo and CT on the economic cost …
antihypertensive therapy (CT) compared with placebo and CT on the economic cost …
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence
LM Ruilope, J Segura - Clinical therapeutics, 2003 - Elsevier
Background: End-stage renal disease (ESRD) in patients with type 2 diabetes mellitus (DM)
is associated with a bleak prognosis. The life span of patients with DM who have undergone …
is associated with a bleak prognosis. The life span of patients with DM who have undergone …